NCT04955951

Brief Summary

Non-atopic dermatitis (NAD) or eczema is a common inflammatory condition; potentially debilitating that can compromise quality of life. It is usually seen in childhood, but can onset within or persist into adulthood.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jul 2021

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 16, 2021

Completed
15 days until next milestone

Study Start

First participant enrolled

July 1, 2021

Completed
8 days until next milestone

First Posted

Study publicly available on registry

July 9, 2021

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 15, 2021

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

January 15, 2022

Completed
Last Updated

August 23, 2023

Status Verified

October 1, 2021

Enrollment Period

3 months

First QC Date

June 16, 2021

Last Update Submit

August 20, 2023

Conditions

Chronic Atopic Dermatitis

Outcome Measures

Primary Outcomes (1)

  • Ultrasonography

    Ultrasound imaging system used to measure the thickness of the skin at the site of scale for both groups

    1-2 months

Secondary Outcomes (1)

  • SCORAD Score

    1-2 months

Study Arms (2)

polarized light group

group A (20 patients) will receive Polarized light therapy

Device: polarized light

topical corticosteroid group

group B (20 patients) will receive topical corticosteroid therapy

Drug: Topical corticosteroid ointment

Interventions

polarized lightDEVICE

A Bioptron light therapy phototherapeutic device (Bioptron AG, Wollerau, Switzerland) with 5 cm treatment diameter (BIOPTRON MedAll®, 480-3400 nm, polarization level of 95%, power density 40 mW/cm2, energy density 2,4 J/cm2 per minute

polarized light group
Topical corticosteroid ointmentDRUG

corticosteroid 1 %.

topical corticosteroid group

Eligibility Criteria

Age20 Years - 30 Years
Sexmale(Gender-based eligibility)
Gender Eligibility Details20-30
Healthy VolunteersNo
Age GroupsAdult (18-64)
Sampling MethodProbability Sample
Study Population

The Patient will be referred to physical therapy outpatient clinic, faculty of physical therapy, Ahram Canadian University from dermatology out-clinics in Sheikh Zayed Hospital.

You may qualify if:

  • The patients' ages will ranged from 20 to 30 years.
  • The subjects will be males.
  • The duration of disease less than 1 year.

You may not qualify if:

  • patients who had skin malignancy in the area to be treated.
  • The patients who had history of diabetes, circulatory or sensory disorders.
  • Patients with acute infection in the area treated.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ahram Canadian University

Giza, Egypt

Location

MeSH Terms

Interventions

Microscopy, Polarization

Intervention Hierarchy (Ancestors)

MicroscopyDiagnostic ImagingDiagnostic Techniques and ProceduresDiagnosisInvestigative Techniques

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
LECTURER

Study Record Dates

First Submitted

June 16, 2021

First Posted

July 9, 2021

Study Start

July 1, 2021

Primary Completion

September 15, 2021

Study Completion

January 15, 2022

Last Updated

August 23, 2023

Record last verified: 2021-10

Locations

EG(1)